Dr Reddy’s shares drop 4% as semaglutide Canada delays

What moved the stock in Friday’s trade

Dr Reddy’s Laboratories shares slipped after a period of gains that were linked to market expectations around semaglutide approval in Canada. During the session, the stock erased early gains and fell as much as 4% to an intraday low of ₹1,220.20. The move came as brokerages turned more cautious on near-term catalysts, and as investors weighed recent earnings pressure and ongoing price erosion risks in key markets. The stock action reflected how quickly sentiment can change when a widely discussed trigger faces regulatory uncertainty or a weaker-than-expected earnings backdrop. The reaction also highlights that a rally driven by expectations can unwind when investors reassess timelines and the competitive landscape.

Brokerages turn cautious after a rally

Brokerage commentary pointed to a mismatch between the optimism priced in and the durability of the opportunity. One note said the company’s recent 9% rally on unconfirmed generic semaglutide approval news in Canada likely overstated the upside. The same commentary flagged that even if approval comes through, the Ozempic opportunity in Canada may be short-lived due to faster competition. Goldman Sachs also highlighted that the company’s near-term pipeline remains limited to Ozempic and the Abatacept biosimilar, while price erosion in base products remains a concern. Citi and Goldman Sachs were cited as having downgraded the stock, with competition risk a central theme.

Company clarification on semaglutide: DINs received, approval pending

Dr Reddy’s addressed the market chatter by stating that it has not yet received approval, referred to as the “Notice of Compliance,” for its Semaglutide Injection from Health Canada. The company also disclosed that as part of the regulatory review process, it received “Drug Identification Numbers (DINs)” for Semaglutide Injection from Health Canada on April 22, 2026. It said it continues to engage with the regulator and remains committed to bringing the product to the Canadian market upon approval. For investors, the clarification matters because DINs indicate progress in the process, but they do not equate to marketing authorisation in the form of a Notice of Compliance.

A separate Canada setback: Notice of Non-Compliance raised timeline risk

The semaglutide timeline has already faced scrutiny following an earlier regulatory update from Canada. Dr Reddy’s shares fell nearly 6% on October 30, 2025, after the company said it received a Notice of Non-Compliance from Canada’s Pharmaceutical Drugs Directorate for its Abbreviated New Drug Submission for Semaglutide Injection. The notice sought additional information and clarifications on specific aspects of the submission, raising concerns about a regulatory delay. Dr Reddy’s told exchanges it would submit a response within the stipulated time and said it remained confident in the quality, safety, and comparability of the proposed product. The development was seen as a risk to the company’s planned entry into the Canadian market with semaglutide.

Q4FY26: Profit fell 86% YoY as Lenalidomide tapered

The company’s quarterly performance has been another pressure point in the debate around valuation and near-term visibility. Dr Reddy’s reported that its Q4 profit declined 86% year-on-year, attributed to a significant drop in revenue, a decrease in EBITDA, and a reduction in gross margin. The company cited lower sales of Lenalidomide, price erosion in North America and Europe Generics, and a one-time Shelf Stock Adjustment (SSA) of ₹450 crore related to the product. Revenue for Q4FY26 dropped due to a 51% YoY decline in the North American market, primarily from lower Lenalidomide sales and the one-time SSA. Global generics fell 13% YoY, and pharmaceutical services and active ingredients revenue decreased 5% YoY.

Q3 FY25-26: Mixed operating picture, margins under pressure

Another set of numbers in the recent run-up also showed the strain from pricing pressure and changing product mix. Revenue for the quarter grew 16% year-on-year to ₹8,359 crore, supported by new product launches and operational efficiencies. North America revenue rose 1% year-on-year to ₹3,380 crore, with new launches helping volumes but lower pricing offsetting gains. The quarter also saw a sequential decline linked to reduced sales of Lenalidomide (generic Revlimid). EBITDA margin narrowed to 27.5% from 29.3% a year earlier, with pricing pressures in the US market and declining contribution from key products cited.

Technical and ratings triggers added to the selling pressure

Beyond earnings, some market commentary focused on technical signals and near-term trend deterioration. MarketsMOJO downgraded Dr Reddy’s Laboratories from Hold to Sell on March 23, 2026, citing disappointing quarterly results and a shift in technical indicators from sideways to mildly bearish. The note cited Profit Before Tax (excluding other income) falling 18.3% to ₹1,274.40 crore and Profit After Tax falling 16.2% to ₹1,209.90 crore compared with the previous four-quarter average. On the day referenced, the stock was down 3.57% to ₹1,252.55 from a previous close of ₹1,298.95, and it was trading within a 52-week range of ₹1,025.90 to ₹1,377.95.

Other overhangs: tax notice and broader trade-risk headlines

Dr Reddy’s has also faced non-operational headlines that have triggered sharp single-day moves. The stock fell as much as 7.55% to an intraday low of ₹1,025.90 after the company disclosed a show cause notice of about ₹2,395.82 crore from the income tax department, linked to reassessment proceedings for Assessment Year 2020-21. Separately, export-oriented stocks, including pharmaceuticals, were affected when US political signals raised fears of significantly higher import duties, and the Nifty Pharma index declined 1.5% after a warning of a 25% tariff on Indian goods starting August 1. These factors added to volatility even when company-specific fundamentals were the primary driver.

Key numbers and events at a glance

Market impact: why these inputs matter for valuation

The sell-off underscores that the stock’s near-term narrative is being shaped by two linked variables: the durability of post-Lenalidomide earnings and the timing of semaglutide-related upside. The Q4FY26 profitability drop and the North America decline described in the article show how quickly a key product can swing the quarterly base, particularly when combined with one-offs like the SSA. At the same time, broker commentary suggests investors are now discounting the “first-mover” benefits in Canada if regulatory timelines stretch and competition accelerates. With price erosion cited in North America and Europe generics, the market is also assessing whether core products can defend margins while the pipeline remains concentrated in a few large opportunities.

Analysis: pipeline concentration and regulatory sequencing are in focus

Two things stand out from the information disclosed. First, the company’s own statement separates DIN receipt from a Notice of Compliance, which reduces the scope for misinterpretation around approval status. Second, the discussion from multiple brokerages emphasises that even a positive regulatory outcome may not translate into a long, uncontested earnings tail if competitors enter quickly. Against that backdrop, the steep year-on-year profit decline in Q4FY26 and margin compression in Q3 reinforce why investors are sensitive to incremental negatives on timing or competition. This combination tends to increase volatility because the valuation becomes more dependent on event-driven outcomes rather than steady base-growth visibility.

Conclusion

Dr Reddy’s latest decline followed broker downgrades and renewed scrutiny of near-term earnings quality after weak profitability trends and product-led volatility. The company has clarified that it has not yet received Health Canada’s Notice of Compliance for semaglutide, even as it has obtained DINs dated April 22, 2026. The next market cues are likely to come from further regulatory updates on semaglutide in Canada and the company’s ability to offset Lenalidomide-related pressures and pricing erosion in core markets.